Viridian Therapeutics, Inc. (0K1R.L)
USD 13.33
(-8.32%)
USD 13.33
(-8.32%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 21.04 Million USD | 300.3% |
| 2022 | 5.25 Million USD | 911.15% |
| 2021 | 520 Thousand USD | 14.29% |
| 2020 | 455 Thousand USD | -94.52% |
| 2019 | 8.3 Million USD | -19.36% |
| 2018 | 10.29 Million USD | 3.79% |
| 2017 | 9.92 Million USD | 849.47% |
| 2016 | 1.04 Million USD | -5.43% |
| 2015 | 1.1 Million USD | 1281.25% |
| 2014 | 80 Thousand USD | -88.52% |
| 2013 | 697.06 Thousand USD | -96.92% |
| 2012 | 22.62 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 21.95 Million USD | 4.31% |
| 2024 Q2 | 20.95 Million USD | -4.55% |
| 2023 Q2 | 5.51 Million USD | 3.71% |
| 2023 Q3 | 20.82 Million USD | 277.81% |
| 2023 Q4 | 21.04 Million USD | 1.09% |
| 2023 FY | 21.04 Million USD | 300.3% |
| 2023 Q1 | 5.31 Million USD | 1.07% |
| 2022 Q1 | 579 Thousand USD | 11.35% |
| 2022 Q3 | 5.17 Million USD | 0.23% |
| 2022 Q2 | 5.16 Million USD | 792.06% |
| 2022 Q4 | 5.25 Million USD | 1.56% |
| 2022 FY | 5.25 Million USD | 911.15% |
| 2021 Q1 | 355 Thousand USD | -21.98% |
| 2021 Q3 | 430 Thousand USD | 4.37% |
| 2021 Q4 | 520 Thousand USD | 20.93% |
| 2021 FY | 520 Thousand USD | 14.29% |
| 2021 Q2 | 412 Thousand USD | 16.06% |
| 2020 Q1 | 7.67 Million USD | -7.61% |
| 2020 Q2 | 9.19 Million USD | 19.84% |
| 2020 FY | 455 Thousand USD | -94.52% |
| 2020 Q4 | 455 Thousand USD | -95.08% |
| 2020 Q3 | 9.24 Million USD | 0.5% |
| 2019 Q2 | 10.15 Million USD | -2.32% |
| 2019 FY | 8.3 Million USD | -19.36% |
| 2019 Q4 | 8.3 Million USD | -10.04% |
| 2019 Q3 | 9.23 Million USD | -9.06% |
| 2019 Q1 | 10.39 Million USD | 0.91% |
| 2018 FY | 10.29 Million USD | 3.79% |
| 2018 Q1 | 10.01 Million USD | 0.97% |
| 2018 Q3 | 10.2 Million USD | 0.93% |
| 2018 Q4 | 10.29 Million USD | 0.91% |
| 2018 Q2 | 10.11 Million USD | 0.93% |
| 2017 Q1 | 4.32 Million USD | 313.49% |
| 2017 FY | 9.92 Million USD | 849.47% |
| 2017 Q4 | 9.92 Million USD | 194.07% |
| 2017 Q3 | 3.37 Million USD | -12.36% |
| 2017 Q2 | 3.85 Million USD | -10.9% |
| 2016 Q3 | 1.1 Million USD | 0.0% |
| 2016 Q4 | 1.04 Million USD | -5.43% |
| 2016 Q2 | 1.1 Million USD | 0.0% |
| 2016 Q1 | 1.1 Million USD | 0.0% |
| 2016 FY | 1.04 Million USD | -5.43% |
| 2015 Q4 | 1.1 Million USD | 0.0% |
| 2015 Q1 | 1.05 Million USD | 1222.5% |
| 2015 FY | 1.1 Million USD | 1281.25% |
| 2015 Q3 | 1.1 Million USD | 0.0% |
| 2015 Q2 | 1.1 Million USD | 4.44% |
| 2014 Q4 | 80 Thousand USD | 654.93% |
| 2014 Q1 | 1 Million USD | 44.68% |
| 2014 Q2 | 10.59 Thousand USD | -98.95% |
| 2014 Q3 | 10.59 Thousand USD | 0.0% |
| 2014 FY | 80 Thousand USD | -88.52% |
| 2013 Q4 | 697.06 Thousand USD | 0.0% |
| 2013 FY | 697.06 Thousand USD | -96.92% |
| 2012 FY | 22.62 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 229.19 Million USD | 90.816% |
| Arrowhead Pharmaceuticals, Inc. | 115.17 Million USD | 81.725% |
| Codexis, Inc. | 22.36 Million USD | 5.884% |
| Organovo Holdings, Inc. | 1.39 Million USD | -1409.9% |